Management of Extrapyramidal Symptoms (EPS)

Introduction to EPS Management

The American Academy of Child and Adolescent Psychiatry recommends immediate treatment with anticholinergic medications (benztropine 1-2 mg IM/IV) or antihistamines (diphenhydramine) for acute dystonia, providing rapid relief 1, 2
The American College of Psychiatry suggests that young males are at highest risk for dystonic reactions, particularly when using high-potency typical antipsychotics like haloperidol 1, 2

Acute dystonia is characterized by sudden spastic muscle contractions, typically occurring within the first 3-5 days of antipsychotic treatment, most commonly affecting the neck, eyes (oculogyric crisis), or torso 1
Drug-induced parkinsonism symptoms include bradykinesia, tremors, and rigidity, appearing within the first three months of treatment due to dopamine D2 receptor blockade 1, 2
Akathisia is a severe subjective restlessness with motor agitation (pacing, inability to sit still), commonly misinterpreted as psychotic agitation or anxiety 1, 2
Tardive dyskinesia involves involuntary choreic or athetoid movements, typically orofacial, associated with long-term antipsychotic use 1, 2

The American Psychiatric Association notes that quetiapine has the lowest EPS risk among commonly used antipsychotics 2, 3
Aripiprazole has low EPS risk but requires careful dosing 3
Olanzapine and clozapine have moderate-to-low EPS risk 2, 3
Risperidone has higher EPS risk, especially at doses exceeding 2-6 mg/day 3
Typical antipsychotics (haloperidol, chlorpromazine) have the highest EPS risk 1, 2, 3

Anticholinergic medications should NOT be used routinely for preventing EPS but reserved for treatment of significant symptoms when dose reduction and switching strategies have failed, as recommended by the American College of Psychiatry 2, 4
Consider prophylactic anticholinergics only in high-risk patients: young males, those with history of dystonic reactions, or paranoid patients where compliance is critical 1
Reevaluate need for anticholinergics after the acute treatment phase or if antipsychotic doses are lowered, as many patients no longer need them during long-term therapy 1
Avoid anticholinergics in elderly patients due to heightened sensitivity causing delirium, drowsiness, and paradoxical agitation 2, 4

Children and adolescents may be at higher risk for EPS than adults and have greater difficulty communicating concerns due to developmental issues, according to the American Academy of Child and Adolescent Psychiatry 1
Elderly patients should use quetiapine (starting 25 mg PO) as preferred antipsychotic when minimizing EPS is priority 3, 4
Avoid typical antipsychotics in elderly patients due to significant cholinergic, cardiovascular, and extrapyramidal side effects 3
Haloperidol is contraindicated in patients with Parkinson's disease or dementia with Lewy bodies due to severe EPS risk 4

Regular monitoring for early signs of EPS is essential throughout antipsychotic treatment, as recommended by the American College of Psychiatry 2
Akathisia is frequently misdiagnosed as anxiety or psychotic agitation, leading to inappropriate dose increases that worsen the problem 1, 2
Anticholinergic medications can worsen delirium in patients with anticholinergic drug intoxication, according to the American Academy of Pediatrics 5
Monitor for orthostatic hypotension, especially with quetiapine during initial dose titration 3
Avoid combining quetiapine with benzodiazepines when possible due to increased sedation risk 3

Use the lowest effective antipsychotic dose and avoid rapid dose escalation, as recommended by the American College of Psychiatry 2
For risperidone in elderly: start 0.25-0.5 mg daily; EPS risk increases significantly above 2 mg daily 3, 4
For olanzapine in elderly: start 2.5-5 mg daily with moderate EPS risk 3, 4
For quetiapine in elderly: start 25 mg every 12 hours; maximum typically 200 mg twice daily 3